Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acalabrutinib + bendamustine + rituximab
- Development stage
- Unknown
- Lead developer
- AstraZeneca
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous, Subcutaneous
01
Overview
Acalabrutinib + bendamustine + rituximab is a three-drug combination regimen approved for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous hematopoietic stem cell transplantation. Acalabrutinib is a selective Bruton tyrosine kinase (BTK) inhibitor that blocks B-cell receptor signaling and proliferation. Bendamustine is an alkylating agent that causes DNA crosslinking and apoptosis in malignant cells. Rituximab is a monoclonal antibody targeting CD20 on B lymphocytes leading to their depletion. The combination has demonstrated improved progression-free survival compared to chemoimmunotherapy alone in clinical trials[1][2][3][4][5].
- Brand names
- Rituxan Hycela
- Other names
- ABR (for the combination)BR (for bendamustine + rituximab)
02
Targets
Beyond the preview
Go deeper on acalabrutinib + bendamustine + rituximab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on acalabrutinib + bendamustine + rituximab.